



October 19, 2010 09:00 AM Eastern Daylight Time

## Retina Implant Presents Clinical Trial Results at the American Academy of Ophthalmology Annual Meeting

*Subretinal Approach to Retinal Implant Technology in the Spotlight at Key Industry Event*

REUTLINGEN, Germany--(BUSINESS WIRE)--Retina Implant AG, a leading developer of subretinal implants for the visually impaired, is proud to announce Co-Founder and Chairman Eberhart Zrenner, M.D. was invited to present the exciting results of clinical trials he has been leading since 2005 by the American Academy of Ophthalmology at this year's annual meeting that took place October 16-19 at McCormick Place in Chicago, Ill.

Due to personal reasons, Dr. Zrenner was unable to attend. Dr. Walter-G. Wrobel, CEO of Retina Implant AG, delivered the presentation titled, "Subretinal Implants for Retinitis Pigmentosa" as part of AAO's Retina Subspecialty Day on Saturday, October 16. The presentation discussed findings from Retina Implant's first clinical trial which began in November 2005 and involved implanting 11 patients with a 1500 electrode microchip subretinally. Dr. Wrobel explained how the trial was carried out, the subretinal technique to implantation, and the visual results achieved by patients including the ability to recognize foreign objects and read at a basic level.

**"The stellar results achieved during our first clinical trial validate our subretinal approach to implantation which we believe is the key to restoring useful vision for patients blind by retinitis pigmentosa"**

"The stellar results achieved during our first clinical trial validate our subretinal approach to implantation which we believe is the key to restoring useful vision for patients blind by retinitis pigmentosa," said Walter-G. Wrobel, CEO of Retina Implant AG. "As we continue on with our second clinical trial, we look forward to expanding on the lessons learned during our first trial by following patients as they return home."

Retina Implant began their second clinical trial earlier this year in Germany with plans to expand the trial to other European countries including the U.K. and Italy. In this clinical trial patients will receive the 1500 electrode implant permanently. Pending positive results from their second clinical trial, Retina Implant intends to submit for CE mark approval.

### About Retina Implant AG

Retina Implant AG is the leading developer of subretinal implants for partially sighted and blind patients. After extensive research with German university hospitals and institutes which began with a large grant from the German Federal Ministry of Research and Education in 1996, Retina Implant AG was founded by Dr. Eberhart Zrenner and his colleagues in 2003 with private investors with the goal of developing the first fully-functioning electronic retinal implant to restore useful vision to the blind. Retina Implant began implanting in human patients in 2005, and has started a second clinical trial this year. To learn more visit <http://www.retina-implant.de/>.

### Contacts

Schwartz Communications:  
Sherry Feldberg / Kirsten Fallon  
781-684-0770  
[RetinaImplant@schwartzcomm.com](mailto:RetinaImplant@schwartzcomm.com)

or

Retina Implant, AG.:  
Dr. Walter-G. Wrobel  
+ 49 7121 | 36403-111  
[Walter.Wrobel@retina-implant.de](mailto:Walter.Wrobel@retina-implant.de)

**Permalink:** <http://www.businesswire.com/news/topix/20101019005693/en/Retina-Implant-Presents-Clinical-Trial-Results-American>

### Sharing



[Get Business Wire News on Your Website](#)

---

[Terms of Use](#) | [©2010 Business Wire](#)

---